Amarin (AMRN) vs Pfizer (PFE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pfizer (PFE) has outperformed Amarin (AMRN) over the past year, gaining 6.6% versus a loss of 37.6%. Over five years, PFE leads with a -32.5% price change compared with -88.4% for AMRN. Pfizer is the larger company by market cap ($157.58 billion vs $250.4 million), about 629.3 times the size.
On valuation, Pfizer trades at a lower forward P/E (9.5x vs 12.1x for Amarin). Pfizer pays a dividend yielding 6.22%, while Amarin does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | PFE |
|---|---|---|
| Share price | $11.86 | $27.65 |
| Market cap | $250.41M | $157.58B |
| 1-day change | -1.37% | -1.26% |
| YTD return | -13.90% | +12.45% |
| 1-year return | -37.62% | +6.59% |
| 5-year return | -88.35% | -32.51% |
| P/E ratio (TTM) | — | 36.38 |
| Forward P/E | 12.10 | 9.54 |
| EPS (TTM) | $-1.20 | $0.76 |
| Dividend yield | 0.00% | 6.22% |
| Annual dividend | $0.00 | $1.72 |
| Revenue (latest FY) | — | $62.58B |
| Revenue growth (YoY) | — | -1.65% |
| Net income (latest FY) | — | $7.77B |
| Gross margin | — | 74.33% |
| Net margin | — | 12.42% |
| 52-week high | $20.90 | $29.21 |
| 52-week low | $11.83 | $23.62 |
| Distance from 52-week high | -43.28% | -5.35% |
| Analyst consensus | none | buy |
| Avg. price target upside | +5.44% | +4.56% |
| Average volume | 66.16K | 35.94M |
| Shares outstanding | 21.12M | 5.70B |
| Employees | 80 | 75,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Pfizer is about 629.3 times larger than Amarin by market value ($157.58B vs $250.41M).
- PFE has outperformed AMRN by 44.2 percentage points over the past year.
- Pfizer offers a meaningfully higher dividend yield (6.22% vs 0.00%).
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About Pfizer
PFE stock →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 75,000 employees
AMRN vs PFE FAQ
Which is bigger, Amarin or Pfizer?
Pfizer (PFE) is larger, with a market capitalization of $157.58B compared with $250.41M for Amarin (AMRN).
Which stock has performed better over the past year, AMRN or PFE?
PFE returned +6.59% over the past 12 months, compared with -37.62% for AMRN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Amarin or Pfizer?
Pfizer pays a dividend yielding 6.22%, while Amarin does not currently pay a regular dividend.
Are Amarin and Pfizer in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.